At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Study of the Role the Microbiome and Diet Plays in Parkinson’s Disease

Clinical Trial Title: 
Study of the role the microbiome and diet plays in Parkinson’s disease by comparing the microbiome of Parkinson’s disease patients to that of healthy controls.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Ali Keshavarzian, MD
Clinical Trial Protocol Description: 

The purpose of this study is to determine the role of microorganisms in the intestine also known as ‘microbiome’ and diet in the pathogenesis of Parkinson's disease (PD). This research may help us answer several questions like how does diet and intestinal microorganisms promote PD pathogenesis. The objective of this aim is to fill the translational knowledge gap between imbalance of the microbiome and PD. We hope to enroll 20 subjects with PD and 20 household healthy controls.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between 40 and 80 years of age.
  • Have a diagnosis of Parkinson’s disease or are a healthy control in the same household as a participating Parkinson’s disease patient or who is a 1st degree relative of a Parkinson’s disease patient.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a history of GI diseases.
  • Have used an antibiotic in the last 12 weeks.
  • Use a probiotic supplement; except yogurt.
  • Have chronic use of NSAIDS.
  • Have had recent intentional change in diet.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Parkinson's Disease and Other Movement Disorders
Contact Phone: 
(312) 563-3892
Contact Name: 
Gabriella Sanzo